Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Gout

Gout

Part of Arthritis

Subtypes of Gout

Gouty tophi wounds 1

11 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Gout

54 trials tracked for Gout: 28 in phase 3 or 4 and 11 with published results. The most-cited published study has 180 citations.

54Trials tracked
28Phase 3 & 4
0Recruiting
11With published results
Phase distribution
Phase 4 11 Phase 3 17 Phase 2 12 Phase 1 4 Other / NA 10
  1. Phase 3 Combining Lesinurad With Allopurinol in Inadequate Responders Completed · 180 cited
  2. Phase 3 Combining Lesinurad With Allopurinol in Inadequate Responders Completed · 166 cited
  3. Phase 4 CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat Completed · 102 cited
  4. Phase 3 PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2) Completed · 95 cited
  5. Phase 3 Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE) Completed · 72 cited
  6. Phase 4 Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout Completed · 65 cited
Show 44 more trials
  1. Phase 4 Colchicine Or Naproxen Treatment for ACute gouT Completed · 64 cited
  2. Phase 4 Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout Completed · 56 cited
  3. Phase 3 Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout Completed · 31 cited
  4. Phase 4 Study of Febuxostat Effect on Blood Pressure in Patients With High Normal Blood Pressure Completed · 26 cited
  5. Phase 4 Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome Completed · 2 cited
  6. Phase 4 Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout Completed
  7. Phase 4 An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels. Completed
  8. Phase 4 Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate Completed
  9. Phase 4 Does Allopurinol Prolong a Treated, Acute Gout Flare? Completed
  10. Phase 4 Allopurinol Outcome Study Completed
  11. Phase 3 Open-Label Lesinurad Monotherapy Extension Study in Gout Completed
  12. Phase 3 Lesinurad and Febuxostat Combination Extension Study in Gout Completed
  13. Phase 3 A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout Completed
  14. Phase 3 Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout Completed
  15. Phase 3 Safety and Efficacy of Oral Febuxostat in Subjects With Gout Completed
  16. Phase 3 Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects. Completed
  17. Phase 3 Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors Completed
  18. Phase 3 MPC-004 for the Treatment of an Acute Gout Flare Completed
  19. Phase 3 Efficacy and Safety of Oral Febuxostat in Participants With Gout Completed
  20. Phase 3 Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010 Completed
  21. Phase 3 Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout Completed
  22. Phase 3 Febuxostat Versus Allopurinol Control Trial in Subjects With Gout Completed
  23. Phase 2 Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout Completed
  24. Phase 2 A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia Completed
  25. Phase 2 A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout Completed
  26. Phase 2 Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients Completed
  27. Phase 2 Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment Completed
  28. Phase 2 RDEA3170 and Febuxostat Combination Study in Gout Subjects Completed
  29. Phase 2 Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions Completed
  30. Phase 2 A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study) Completed
  31. Phase 2 Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares Completed
  32. Phase 2 Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout Completed
  33. Phase 2 Long-Term Safety of Febuxostat in Subjects With Gout. Completed
  34. Phase 2 Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects Completed
  35. Phase 1 RDEA3170 Bioavailability Study Completed
  36. Phase 1 Mild, Moderate and Severe Renal Impairment Study Completed
  37. Phase 1 RDEA3170 and Allopurinol Combination Study in Gout Subjects Completed
  38. Phase 1 Food Effect Study of Febuxostat XR in Healthy Participants Completed
  39. N/A Medication Adherence Patterns in Rheumatic Diseases: A Behavioral Trial Completed
  40. N/A Novel Methods for Ascertainment of Gout Flares -A Pilot Study Completed
  41. N/A Virtual Gout Clinic Completed
  42. N/A Gout Self-Monitoring Aiming to Reach Target Completed
  43. N/A Validation Study of Physical Measurement of Tophi Completed
  44. N/A The Diet Gout Trial Completed

Showing the 50 most-cited and recently-updated of 54 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Hyperuricemia affects 22% of type 2 diabetes patients in global meta-analysis
Diabetes & Endocrinology Meta-analysis
Hyperuricemia affects 22% of type 2 diabetes patients in global meta-analysis Type 2 Diabetes Linked to Higher Risk of Gout
This meta-analysis of 977,573 patients with type 2 diabetes found a pooled hyperuricemia prevalence of 22.0% and gout prevalence of 6.0%. Ri…
A large analysis shows that many people with type 2 diabetes also have high uric acid levels and a higher risk of developing gout.
Frontiers Jun 24, 2026
Gut-joint axis and m6A epigenetic modifications provide a potential mechanism for gout pathophysiology
Diabetes & Endocrinology Sys. Review
Gut-joint axis and m6A epigenetic modifications provide a potential mechanism for gout pathophysiology New theory links gut health to joint pain in gout
This narrative review explores the gut-joint axis and the role of bacterial outer membrane vesicles in gout. The authors propose a Two-Hit f…
A new theoretical model suggests that bacteria in the gut might play a hidden role in causing inflammation and crystal buildup in gouty join…
Frontiers Jun 9, 2026
Review of neutrophil extracellular traps in patients with gout
Allergy & Immunology Sys. Review
Review of neutrophil extracellular traps in patients with gout Your Immune System's Double Agent May Drive Gout Damage
This narrative review examines the role of neutrophil extracellular traps in patients with gout. The authors discuss the biological mechanis…
The same immune webs that fight infections can turn against your joints in gout, and scientists now see them as a hidden driver of long-term…
Frontiers May 13, 2026
Treat-to-target strategy improves gout remission vs symptom-driven care
Rheumatology RCT
Treat-to-target strategy improves gout remission vs symptom-driven care A new gout treatment strategy is changing outcomes
This open-label RCT in 308 adults with gout and hyperuricaemia found that a treat-to-target strategy (urate-guided titration) led to higher …
Many people with gout stay in pain despite treatment, but aiming for a specific uric acid level nearly doubles the chance of remission.
May 3, 2026
Surgical treatment for gouty tophi wounds associated with high healing rates in retrospective study
Orthopedics & Sports Medicine Cohort
Surgical treatment for gouty tophi wounds associated with high healing rates in retrospective study Surgery may help heal gouty tophi wounds
This retrospective cohort study of 130 patients with gouty tophi wounds in China observed high wound healing rates following surgical interv…
A small study shows that surgical treatment, including wound cleaning and vacuum drainage, helped most patients with gouty tophi wounds heal…
Frontiers Apr 30, 2026
Narrative review on macrophage metabolism in gouty arthritis and therapeutic gaps
Drug Pipeline Sys. Review
Narrative review on macrophage metabolism in gouty arthritis and therapeutic gaps Gout inflammation may be stopped by changing cell metabolism
This narrative review examines macrophage metabolic reprogramming in gouty arthritis.
Changing how immune cells burn energy could stop gout pain before it starts, and new nano-delivery systems aim to deliver that fix directly …
Frontiers Apr 29, 2026
UK Biobank observational review links gene-diet interactions to gout risk
Genetics & Precision Medicine
UK Biobank observational review links gene-diet interactions to gout risk Your genes and diet may team up to trigger gout
This observational study from the UK Biobank synthesizes evidence on dietary exposures and gene-diet interactions for cardiometabolic outcom…
A huge UK Biobank study found 20 specific gene-diet interactions linked to health outcomes, including gout. Your genes might influence how f…
medRxiv Apr 23, 2026
Systematic review of gouty arthritis models highlights limitations in reproducing human disease complexity
Diabetes & Endocrinology Sys. Review
Systematic review of gouty arthritis models highlights limitations in reproducing human disease complexity New Gout Models Could Finally Fix Chronic Pain
This systematic review evaluated various gouty arthritis models, including exogenous monosodium urate and hyperuricemia models, as well as c…
Better lab models mean scientists can finally target the root causes of long-term gout pain instead of just hiding the symptoms.
Frontiers Apr 14, 2026
Review of quercetin in metabolic diseases shows promise but lacks clinical validation
Diabetes & Endocrinology RCT
Review of quercetin in metabolic diseases shows promise but lacks clinical validation Review suggests quercetin may have multiple beneficial effects on metabolic conditions
This review evaluates quercetin for conditions including diabetes, obesity, and gout.
A natural compound found in fruits and vegetables shows promise for managing type 2 diabetes, obesity, and fatty liver disease, though human…
Frontiers Apr 13, 2026
Subcutaneous etanercept rapidly alleviated pain and inflammation in 12 acute gout patients compared to methylprednisolone
Rheumatology RCT
Subcutaneous etanercept rapidly alleviated pain and inflammation in 12 acute gout patients compared to methylprednisolone Small study finds etanercept may help acute gout pain like steroids
This single-center, prospective, randomized, open-label study evaluated subcutaneous etanercept versus intravenous methylprednisolone in 12 …
A small study found etanercept provided rapid pain relief for acute gout flares that matched standard steroid treatment with no serious side…
Apr 8, 2026
Febuxostat-Charcoal Combo Fails to Improve Urate Control but Reduces Gout Flares in RCT
Rheumatology RCT
Febuxostat-Charcoal Combo Fails to Improve Urate Control but Reduces Gout Flares in RCT Gout study finds combination treatment reduces flares but not urate levels
A 24-week RCT in 348 primary gout patients found adding activated charcoal to febuxostat 20 mg did not improve serum urate control versus fe…
Adding activated charcoal to gout medication reduced painful flares and cholesterol, but failed to lower urate levels better than standard t…
Apr 4, 2026

Questions about Gout

Are there specific gene-diet interactions that increase my risk for gout?

Research shows that specific gene-diet interactions do increase gout risk, but these genetic factors are not the only drivers of the disease.

Full answer →
How does a treat-to-target strategy compare to symptom-driven care for gout remission?

A treat-to-target strategy that aims for a serum urate level below 0.36 mmol/L leads to better gout remission than symptom-driven care, which relies on starting treatment only when pain occurs.

Full answer →
Can surgery help heal wounds caused by gouty tophi in patients with diabetes?

Yes, surgery can help heal wounds from gouty tophi, but diabetes increases the risk of delayed healing and infection, so careful preoperative management is essential.

Full answer →